Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PROK Catalyst Timeline
Dated clinical, regulatory and corporate events for ProKidney Corp.
Catalyst Timeline
Dated clinical, regulatory & corporate events for ProKidney Corp.
Upcoming catalysts 2
Event history 50
Past FDA Catalysts and PDUFA Decisions
How PROK actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-23 | rilparencel (REACT) | Phase 2 data presentation | Phase 2 |
Drug Pipeline Intelligence
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Rilparencel Cell TherapiesNCT05099770 | Type 2 Diabetes Mellitus | Phase 3 | ACTIVE NOT_RECRUITING | 778 | Dec 1, 2029 | ||||||
| Rilparencel Cell TherapiesCompletedNCT04115345 | Chronic Kidney Disease | Phase 2 | COMPLETED | 59 | Jan 31, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every PROK program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| rilparencel AcceleratedRMAT | advanced CKD and type 2 diabetes mellitus | Phase 2 | 2026-10-22 | strong safety profile and kidney function stabilizationRead More | ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Pereira Brian JGDirector | Sell | -222,948 | $1.42 | 08/20/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PROK
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in PROK for Q2 2026. | ||||
Ownership Trends
PROK Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How PROK ranks across every disease it competes in
PROK News
ProKidney to Host Virtual KOL Event to Recap Mechanism of Action Data Presented at ASN Kidney Week and Provide a Corporate Update
ProKidney Corp. announced a virtual KOL event on October 27, 2026, to discuss insights into rilparencel's mechanism of action. Nephrology expert Katherine Tuttle will join company management to review findings from ASN Kidney Week 2026. The event aims to address the unmet needs in treating advanced CKD and type 2 diabetes.
Read more →ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026
ProKidney Corp. announced eight abstracts for presentation at the American Society of Nephrology's Kidney Week 2026. Notably, one clinical abstract indicates a strong safety profile and kidney function stabilization in advanced CKD patients. The data supports the multifactorial mechanism of action for rilparencel, enhancing confidence in the ongoing Phase 3 PROACT 1 study.
Read more →ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights
ProKidney reported a net loss of $46.4 million for the second quarter of 2026. The company ended the period with $181.6 million in cash and marketable securities. Research and development expenses rose to $36.1 million from $25.9 million a year earlier. ProKidney also completed enrollment for the accelerated approval analysis of its Phase 3 PROACT 1 study.
Read more →ProKidney Appoints Kenneth Locke as Chief Technical Officer
ProKidney Corp. has appointed Kenneth Locke as Chief Technical Officer to enhance its technical foundation as it prepares for a pivotal topline readout in Q2 2027. Locke brings extensive experience from Carisma Therapeutics and Celgene, where he led key manufacturing and regulatory functions. His leadership is expected to be vital as ProKidney advances its Phase 3 study for its autologous cell therapy targeting chronic kidney disease.
Read more →ProKidney Reports First Quarter 2026 Financial Results and Business Highlights
ProKidney Corp. reported its Q1 2026 financial results, highlighting progress in its Phase 3 PROACT 1 study for rilparencel, which is expected to complete enrollment by mid-2026. The company ended the quarter with $224.9 million in cash, supporting operations into mid-2027. Positive Phase 2 results were published, and FDA alignment on the accelerated approval pathway was confirmed.
Read more →ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer
ProKidney Corp. has appointed Greg Madison as Chief Commercial Officer to lead the company's commercial strategy as it advances the cell therapy rilparencel towards potential commercialization. Madison brings over two decades of experience in biopharma, having previously held leadership roles at Shield Therapeutics and Keryx Biopharmaceuticals. His expertise in nephrology will be crucial as ProKidney aims to address unmet needs in chronic kidney disease treatment.
Read more →ProKidney Reports Full Year 2025 Financial Results and Business Highlights
ProKidney Corp. reported its financial results for 2025, highlighting significant progress in its Phase 3 PROACT 1 study for rilparencel, with completion of enrollment expected by mid-2026. The company has aligned with the FDA on an accelerated approval pathway, using eGFR slope as a surrogate endpoint. Financially, ProKidney ended 2025 with $270 million in cash, supporting operations into mid-2027.
Read more →This presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. ProKidney's actual results m
ProKidney is advancing its Phase 3 trial for Rilparencel, an autologous cell therapy for chronic kidney disease (CKD), aiming for potential accelerated FDA approval. The company has reported promising results from earlier trials, indicating that this treatment could stabilize kidney function. However, numerous risks hang over their operations, including potential disruptions following domestication to the U.S. and difficulties in obtaining regulatory approvals. Expectations for a Biologics License Application submission are set for 2H 2027, with several essential milestones planned for 2026.
Read more →ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference
ProKidney Corp. announced that its CEO, Dr. Bruce Culleton, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The company, which focuses on chronic kidney disease (CKD) treatment through cell therapy, is expected to engage in one-on-one meetings with investors during the event. ProKidney's lead product, rilparencel, is currently undergoing a Phase 3 clinical trial aimed at preserving kidney function in patients with advanced CKD and type 2 diabetes.
Read more →ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
ProKidney Corp. reported its third quarter 2025 financial results, highlighting promising Phase 2 data for rilparencel in chronic kidney disease (CKD) patients. The FDA has confirmed that the eGFR slope can serve as a surrogate endpoint for accelerated approval. The company has sufficient cash to support operations through mid-2027, although it continues to incur significant losses.
Read more →ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025
ProKidney Corp. presented full results from the Phase 2 REGEN-007 trial of rilparencel at ASN Kidney Week 2025. The data indicates that rilparencel may preserve kidney function in patients with advanced chronic kidney disease (CKD) and diabetes. This trial supports the ongoing Phase 3 PROACT 1 study, which aims to evaluate the efficacy of rilparencel further.
Read more →ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference
ProKidney Corp. will participate in two significant healthcare conferences in November 2025. The Guggenheim Healthcare Innovation Conference will feature a fireside chat, while the Jefferies Global Healthcare Conference will include one-on-one meetings. These events aim to enhance investor engagement and showcase ProKidney's advancements in chronic kidney disease treatments.
Read more →ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2025
ProKidney Corp. announced the acceptance of two abstracts for presentation at the American Society of Nephrology's Kidney Week 2025. This includes a late-breaking poster on the Phase 2 REGEN-007 study results. The event will take place from November 6-9, 2025, in Houston, TX, showcasing advancements in cellular therapy for chronic kidney disease.
Read more →ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference
ProKidney Corp. will participate in the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference in September. The company's management team will engage in discussions about their innovative cellular therapies for chronic kidney disease. ProKidney's lead product, rilparencel, is currently in a Phase 3 study aimed at preserving kidney function.
Read more →ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
ProKidney Corp. has reported positive developments regarding their treatment rilparencel for chronic kidney disease (CKD) and diabetes. The FDA has confirmed that estimated glomerular filtration rate (eGFR) slope is an acceptable surrogate endpoint for accelerated approval, a decision made in a recent Type B meeting. In an encouraging announcement, the company revealed a 78% improvement in eGFR slope during Phase 2 REGEN-007 and has successfully enrolled more than half of the patients needed for their Phase 3 PROACT 1 study. However, the company also reported a $37 million net loss for Q2 2025, impacting their financial outlook.
Read more →ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel
ProKidney Corp. has confirmed alignment with the FDA on the accelerated approval pathway for its cellular therapy, rilparencel, aimed at treating chronic kidney disease (CKD). The FDA has accepted the eGFR slope as a surrogate endpoint for a Biologics License Application (BLA). ProKidney anticipates topline data readout in Q2 2027 and has nearly completed patient enrollment for the analysis.
Read more →ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference
ProKidney Corp. announced its participation in the H.C. Wainwright 4th Annual Kidney Virtual Conference. Senior management will engage in discussions about their advancements in cellular therapeutics for chronic kidney disease. The company's lead product, rilparencel, is under evaluation in Phase 2 and Phase 3 studies and has received FDA's RMAT designation.
Read more →ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes
ProKidney Corp. announced positive topline results from the Phase 2 REGEN-007 trial of rilparencel in patients with chronic kidney disease and diabetes. The trial demonstrated a statistically significant improvement in the estimated glomerular filtration rate (eGFR) slope. The company plans to present full results at the ASN 2025 Kidney Week and has an upcoming FDA Type B meeting to discuss accelerated approval pathways.
Read more →